Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
C
311690
vs
K
KOSPI 200
Over the past 12 months, CJ Bioscience Inc has underperformed KOSPI 200, delivering a return of -61% compared to KOSPI 200's +54% growth.
Stocks Performance
311690 vs KOSPI 200
Performance Gap
311690 vs KOSPI 200
Performance By Year
311690 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
CJ Bioscience Inc
Glance View
CJ Bioscience is a South Korean biotechnology company focused on the human microbiome, the community of bacteria that live in and on the body. It develops tests, analysis tools, and drug candidates built around microbiome data, using sequencing and bioinformatics to study how gut microbes relate to health and disease. In simple terms, it tries to turn microbial data into useful products for diagnosis, research, and treatment. The company serves pharmaceutical companies, research institutions, hospitals, and other life-science customers that need microbiome analysis or want to build microbiome-based therapies. It makes money by selling research services, analytical products, and software or data tools, and by working with partners on drug development programs. Some of its value also comes from helping customers interpret complex biological samples that are hard to analyze with standard lab methods. What makes CJ Bioscience different is its role at the intersection of diagnostics, data analysis, and drug discovery. Instead of selling a broad range of medicines, it is tied to a specialized scientific niche where the main asset is microbiome know-how and the ability to convert raw sequence data into actionable insights. That makes it a toolmaker and research partner as much as a biotech developer.